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Psoriasis is a chronic skin disorder with multifactorial etiology. In a recent study, we reported results of a genome-wide scan on 46
French extended families presenting with plaque psoriasis. In addition to unambiguous linkage to the major susceptibility locus
PSORS1 on Chromosome 6p21, we provided evidence for a susceptibility locus on Chromosome 20p13. To follow up this novel
psoriasis susceptibility locus we used a family-based association test (FBAT) for an association scan over the 17 Mb candidate
region. A total of 85 uncorrelated SNP markers located in 65 genes of the region were initially investigated in the same set of large
families used for the genome wide search, which consisted of 295 nuclear families. When positive association was obtained for
a SNP, candidate genes nearby were explored more in detail using a denser set of SNPs. Thus, the gene ADAM33 was found to be
significantly associated with psoriasis in this family set (The best association was on a 3-SNP haplotype P=0.00004, based on
1,000,000 permutations). This association was independent of PSORS1. ADAM33 has been previously associated with asthma,
which demonstrates that immune system diseases may be controlled by common susceptibility genes with general effects on
dermal inflammation and immunity. The identification of ADAM33 as a psoriasis susceptibility gene identified by positional
cloning in an outbred population should provide insights into the pathogenesis and natural history of this common disease.
Citation: Lesueur F, Oudot T, Heath S, Foglio M, Lathrop M, et al (2007) ADAM33, a New Candidate for Psoriasis Susceptibility. PLoS ONE 2(9): e906.
doi:10.1371/journal.pone.0000906
INTRODUCTION
Psoriasis[MIM177900]isacommonhyperproliferativeandchronic
inflammatory skin disease with a prevalence of about 2–4% in
Caucasian populations [1]. Plaque psoriasis, also known as psoriasis
vulgaris, is by far the most common type of psoriasis, accounting for
80%–90% of all psoriasis patients. It appears as raised red scaling
patches, most frequently on the elbows, knees, scalp and lower back.
This autoimmune disease is regarded as a multifactorial trait
involving environmental factors such as intake of certain drugs,
psychosocial stress, smoking, or climate conditions, all of which are
well known triggering factors for primary manifestations or
exacerbation in susceptible individuals [2]. On the other hand,
evidence for a strong genetic component is provided by twin and
family studies, which have shown a concordance rate of psoriasis
in monozygotic twins of 65–72% vs 15–30% in dizygotic twins and
a heritability of 80% [3].
In an attempt to elucidate the genetic basis of psoriasis,
a number of genome-wide linkage studies have been undertaken.
Overwhelming evidence for a susceptibility locus has been found
for Chromosome 6p21 within the HLA region [4–11]. In
particular, association studies employing linkage disequilibrium
(LD) mapping have been successful in narrowing the locus to
a 300kb interval [12–16] and then in identifying HLA-Cw6 as the
disease allele at the 6p21 locus [16,17]. This locus, referred as
PSORS1 (Psoriasis Susceptibility 1, [MIM 177900] contributes to
the familial clustering of disease (l)t o3 3 ,l,50% [5,18].
Therefore, other susceptibility genes are likely to exist. Genome-
wide linkage analyses have highlighted a number of disease loci on
at least 15 chromosomes (see [11] for review). Elucidation of the
disease genes in these candidate loci is hampered by their large size
and by the large number of candidates in each region.
We have recently confirmed the presence of a psoriasis suscep-
tibility locus on Chromosome 20p13, through a genome-wide scan
in French extended families (Peak ZMLB score = 2.9, P =0 . 0 0 2 )
[11]. This region has been previously though to be involved in the
predisposition to psoriasis [4,5] and to other inflammatory disorders
such as atopic dermatitis (AD, also known as eczema) and asthma
[19]. Here we follow up this finding by performing fine mapping of
the 17Mb region using a family-based association study design. To
maximize the chances of success, we investigated the same family set
that was used for the linkage study. A total of 85 intragenic single
nucleotide polymorphisms (SNPs) were initially genotyped and
tested for association independently. When suggestive association
was found for a marker, a denser SNP analysis was carried out to
investigate the candidate genes located in the LD block. Thus, we
describe the identification of ADAM33 as being a novel psoriasis
susceptibility gene. This gene encodes a member of the disintegrin
and metalloprotease domain family of proteins. It has been
previously associated with asthma [20–22], which confirms that
immune system diseases are controlled by common susceptibility
genes with general effects on dermal inflammation and immunity.
However, this association could not be replicated in an independent
set of81 smaller families(173nuclearfamilies,Set II) alsooriginating
from France, indicating that different genetic factors may be
involved in the predisposition to psoriasis in our population.
RESULTS
Stage I: Preliminary screen for SNP-based
association on Chromosome 20p13
The 17Mb candidate locus on 20p13 extended from the telomere
of the short arm of Chromosome 20 (D20S864) to the
microsatellite D20S112 (Figure 1A), and contains 428 known
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e906genes. We aimed to define the boundaries of this region of linkage
and to identify the causative variants. We initially selected 85 SNPs
across the region for genotyping. For all SNPs, genotypes in
founders satisfied the Hardy-Weinberg equilibrium. Figure 1B
illustrates the results of the family-based association test (FBAT)
under the assumption of linkage [23] for the 85 SNPs genotyped in
45 multigenerational families (corresponding to 295 nuclear
families). Position, minor allele frequency, and FBAT results for
all SNPs are given in Supplementary Table S1. Four SNPs showed
some evidence for association to psoriasis (P,0.05): rs12480529
located in the promoter of DEFB127, rs6110460 located in intron
1o fDEFB129, rs512625 located in the 39UTR of ADAM33, and
rs6053417 located in the promoter of AK125948 encoding
a hypothetical protein (Figure 1C).
Stage II: Haplotype analyses of candidate genes at
the 3 loci
We used data from the International HapMap project to look at
patterns of LD surrounding the SNPs showing some association
with psoriasis in the CEPH Caucasian sample set [18]. The
Defensin B (DEFB) gene cluster, ADAM33 and AK125948 were
located in 3 distinct regions (Figure 1C) and the associated markers
were not in LD. To capture most of the genetic variation at the
three loci, and to potentially identify allelic variant(s) predisposing to
psoriasis, a tagging SNP approach was undertaken to test the
c a n d i d a t eg e n e si nt h e3r e g i o n s( s e eP a t i e n t s ,M a t e r i a l sa n dM e t h o d s
section for SNP selection). A total of 63 additional SNPs were
genotyped in the same family set. Sixteen SNPs were genotyped
withinRegion 1, 45 SNPs within Region 2 and 6 SNPs within Region
3 (Figure 1C). There was no evidence for association between the
DEFB genes and psoriasis, nor between AK125948 and psoriasis in
the univariate SNP analyses and in the haplotypes analyses
(Supplementary Table S2). However, association was observed for
four additional SNPs genotyped within Region 2: three of them were
ADAM33 intronic SNPs (rs677044, rs597980, rs44707), and the
fourth one (rs6076542) was in intron 3 of SIGLEC1,ag e n el o c a t e d
5kb from ADAM33. Results of the association tests for the 45 SNPs in
Region 2 are presented in Table 1.
Evidence for effects of combinations of ADAM33
SNPs on the risk of psoriasis
Due to the low pairwise LD (Supplementary Table S3) and to the
elevated number of haplotypes generated at the ADAM33 locus,
haplotypes covering the whole region could not be constructed.
However, because multiple SNPs may act in combination to alter
the risk of psoriasis, transmissions of all possible 2- or 3-SNP
Figure 1. Schematic representation of the psoriasis susceptibility locus on Chromosome 20p13. A. Genetic map of the linkage interval (tel,
telomere; cen, centromere). Position of microsatellites used in the linkage analysis is indicated in centimorgans (cM). B. Z plot for association tests
performed with FBAT under the assumption of linkage, for SNPs selected in Stage I. Position of SNPs is indicated in megabases (Mb). The dotted line
indicates the threshold for significance of the association test (a Z score.3 corresponds to a P,0.05). C. Detailed physical map on the contig
NT_011387.8 at the 3 candidate loci. Positions of the SNPs genotyped in stage I and in stage II are shown with arrows. Red arrows indicate SNPs
showing evidence for association (P#0.05) in stage I; orange arrows indicate SNPs showing evidence for association (P#0.05) in stage II; black arrows
indicate SNPs showing no evidence for association in the univariate analysis.
doi:10.1371/journal.pone.0000906.g001
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e906Table 1. SNPs genotyped at the ADAM33 locus and FBAT results for the univariate analysis.
..................................................................................................................................................
SNP number SNP ID Other name
a Region
b Amino acid Position
c Nucleotide change
d MAF
e P
f Database
1 rs692862 GFRA4 IVS6+1828 bp 3578110 G.A 0.14 0.26 dbSNP
2 rs633924 GFRA4 exon 6, 39UTR 3580057 T.C 0.33 0.36 dbSNP
3 rs2853208 GFRA4 exon 5 P237P 3580823 T.C 0.48 0.26 dbSNP
4 rs6084432 GFRA4 IVS1+347 bp 3583653 G.A 0.16 0.93 HapMap
5 rs512625 ADAM33 IVS22+243 bp 3588378 G.A 0.30 0.04 HapMap
6 rs2787094 V_4 ADAM33 exon 22, 39UTR 3589161 G.C 0.22 0.43 dbSNP
7 rs677044 ADAM33 exon 22, 39UTR 3589431 A.G 0.22 0.03 HapMap
8 rs543749 V_-1 ADAM33 IVS22-33 bp 3589679 G.T 0.12 0.56 dbSNP
9 rs628977 V_-2 ADAM33 IVS22-75 bp 3589721 C.T 0.39 0.17 dbSNP
10 rs2280089 T_+1 ADAM33 IVS20+66 bp 3590127 G.A 0.13 0.74 HapMap
11 rs2280090 T_2 ADAM33 exon 20 P774S 3590205 G.A 0.13 0.58 dbSNP
12 rs2280091 T_1 ADAM33 exon 20 M764T 3590234 A.G 0.14 0.61 HapMap
13 rs574174 ST_+7 ADAM33 IVS20-498 bp 3590694 C.T 0.18 0.35 dbSNP
14 rs597980 ST_+5 ADAM33 IVS19+400 bp 3591165 C.T 0.45 0.04 dbSNP
15 rs44707 ST_+4 ADAM33 IVS19+339 bp 3591226 A.C 0.41 0.01 dbSNP
16 rs598418 ADAM33 IVS19+296 bp 3591269 T.C 0.39 0.12 dbSNP
17 rs2853209 S_+1 ADAM33 IVS19+93 bp 3591472 T.A 0.48 0.12 dbSNP
18 rs3918396 S_1 ADAM33 exon 19 V710I 3591765 G.A 0.09 0.88 dbSNP
19 rs612709 Q_-1 ADAM33 IVS16+21 bp 3592207 G.A 0.13 0.85 dbSNP
20 rs511898 F_+1 ADAM33 IVS6+66 bp 3595085 C.T 0.34 0.29 dbSNP
21 rs2787095 ADAM33 IVS4-191 bp 3595943 G.C 0.39 0.21 HapMap
22 rs487377 ADAM33 IVS2+3808 bp 3598931 G.A 0.19 0.47 dbSNP
23 rs2853213 ADAM33 IVS1+899 bp 3601840 C.G 0.35 0.16 dbSNP
24 rs2853215 ADAM33 IVS1-3516 bp 3606255 G.A 0.27 0.87 HapMap
25 rs535964 ADAM33 IVS1-3747 bp 3606486 C.T 0.35 0.84 dbSNP
26 rs1046919 ADAM33 IVS1-5086 bp 3607825 T.C 0.19 0.09 HapMap
27 rs656635 ADAM33 IVS1-5343 bp 3608082 G.T 0.50 0.70 HapMap
28 rs17701662 SIGLEC1 IVS18+97 bp 3610512 A.T 0.05 0.19 HapMap
29 rs4815596 SIGLEC1 IVS17+186 bp 3611800 G.A 0.14 0.13 HapMap
30 rs3859664 SIGLEC1 IVS17+96 bp 3611891 C.T 0.40 0.46 HapMap
31 rs3827110 SIGLEC1 IVS13+30 bp 3614064 G.C 0.08 0.95 HapMap
32 rs3746638 SIGLEC1 exon 11 A974V 3615333 A.G 0.46 0.63 HapMap
33 rs709012 SIGLEC1 exon 11 P919H 3615498 G.T 0.38 0.80 HapMap
34 rs754526 SIGLEC1 IVS11-330 bp 3615899 A.T 0.05 0.20 HapMap
35 rs525339 SIGLEC1 IVS10+218 bp 3617014 A.G 0.38 0.47 HapMap
36 rs12624921 SIGLEC1 IVS7-153 bp 3620259 A.G 0.05 0.29 HapMap
37 rs12624922 SIGLEC1 IVS7-174 bp 3620280 A.G 0.05 0.20 HapMap
38 rs6139180 SIGLEC1 IVS6+705 bp 3621283 A.G 0.11 0.72 HapMap
39 rs4813636 SIGLEC1 IVS6+280 bp 3621708 A.G 0.37 0.46 HapMap
40 rs1018493 SIGLEC1 exon 6 S502S 3622011 T.C 0.36 0.44 dbSNP
41 rs611847 SIGLEC1 exon 5 N350N 3624022 C.T 0.32 0.85 HapMap
42 rs6076542 SIGLEC1 IVS3+423 bp 3625997 T.C 0.02 0.04 HapMap
43 rs6037651 SIGLEC1 exon 3 M221V 3626436 T.C 0.37 0.26 HapMap
44 rs735710 SIGLEC1 IVS1-5063 bp 3632839 A.G 0.07 0.61 HapMap
45 rs4815597 SIGLEC1 IVS1-9842 bp 3637618 C.T 0.27 0.55 HapMap
aName according to Van Eerdewegh et al. [20]
bPosition according to reference sequence NM_022139 for GFRA4, NM_025220 for ADAM33 and NM_023068 for SIGLEC1
cReference sequence: NT_011387.8, build 36 version 2 of NCBI’s genome annotation
dMost common allele is given first
eMinor Allele Frequency in the studied sample set
fFBAT association test P-value under assumption of linkage
doi:10.1371/journal.pone.0000906.t001
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e906haplotypes to affected individuals were successively examined. The
best association for the 2-SNP haplotypes was obtained for the pair
SNP5/SNP23 (P=0.0005, based on 1,000,000 permutations). But
generally stronger associations were obtained for the 3-SNP
haplotypes. The ten best 3-SNP haplotypes are presented in
Table 2. Associated haplotypes involved exclusively SNPs within
ADAM33, and revealed both risk and protective effects of ADAM33
alleles depending on the SNP combination.
Association of ADAM33 with psoriasis is
independent of HLA-Cw6 status
The 20p13 locus is likely to segregate independently of PSORS1 in
the psoriasis families [11]. However, a potential interaction between
ADAM33 and HLA-Cw6 alleles was tested. HLA-Cw6 positive
patients were identified using SNPs in strong LD with the risk allele
(namely HCR-325 C.T (rs130076), HCR-1723 G.T (rs130079),
HCR-2327 C.G (rs1576) and CDSN971 C.T (rs1062470)
[24,25]. As expected, those markers define a strongly associated
haplotype in our population (P,0.000001 for haplotype H2, based
on 1,000,000 permutations, Supplementary Table S4). Association
between ADAM33 and psoriasis was then monitored using FBAT
when stratifying the families according to the presence or absence of
this risk haplotype. Although the number of informative families was
reduced, the associations between ADAM33 3-SNPs haplotypes and
psoriasis were still observed in the group of patients not carrying
HLA-Cw6, indicating that the 2 loci act independently. As expected,
the associations were less significant in the group of patients carrying
HLA-Cw6, due to the stronger contribution of the 6p21 locus to
psoriasis susceptibility (Supplementary Table S5).
Genetic heterogeneity between large,
multigenerational families and smaller families
segregating psoriasis
We attempted to confirm our findings of association between
ADAM33 and psoriasis in a broader family sample. Thus, a second
set of 81 smaller French families was investigated (Set II). Those
families had not been included in the linkage study due to the low
informativity of the pedigrees for such studies. However, they
represented 173 nuclear families on which the FBAT transmission
disequilibrium test could be performed (Table 3). Therefore, the
15 SNPs contributing to the best combinations were genotyped in
Set II (Table 4). No association was found in the individual or
combined SNP analyses when analyzing Set II independently, but
same 3-SNP haplotype associations were confirmed when
combining Set I and Set II. It is likely that the discrepancy
between the 2 family sets was due to a lower informativity of Set II
because of the difference in the pedigree structures (Table 3).
Indeed, the numbers of informative nuclear families for the 3-SNP
haplotypes giving the best associations in Set I were lower in Set II
than in Set I (Table 2). Moreover, the results of HLA-C tagging
SNPs, known to be strongly associated with psoriasis, illustrated
the weak power of Set II for performing family-based association
tests. For example, for SNP rs1062470, a P of 0.0001 was obtained
for Set I, which had 86.7% (39/45) of informative families,
whereas a P of 0.02 was obtained for Set II but this set had only
50.6% (41/81) of informative families. However, a significant
association was observed for the combined sets (P=0.000006,
Supplementary Table S4).
DISCUSSION
A common genetic component to autoimmune susceptibility had
been initially shown by twin and adoption studies and by increased
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e906risk to siblings [26]. Later, linkage studies demonstrated that
autoimmune diseases share a limited number of loci [27,28],
reinforcing the idea that common susceptibility genes control
them. Recently, we identified a susceptibility locus for psoriasis on
Chromosome 20p13 [11], a region also linked to AD and asthma,
two other inflammatory disorders [19]. Here, using a family-based
association design to interrogate the locus, we identified several
combinations of SNPs within ADAM33, a gene that has been
associated with asthma in many studies, to be strongly associated
with psoriasis in multigenerational French families.
Due to the large number of all possible 2- and 3-SNP combina-
tions tested, the issue of multiple testing should be addressed here.
A Bonferroni correction, although too conservative because the
SNPs in the candidate region were all correlated, could be applied.
When considering all possible 2-SNP combinations with one of the
5 SNPs associated in the univariate analysis, 110 tests are
performed. Therefore, the threshold for a significant P-value
should be ,0.00045. The best 2-SNP combination (SNP5/
SNP23) gives a P=0.0005, based on 1,000,000 permutations, in
favour of a significant association with psoriasis. Moreover, these 2
SNPs are also included in some of the best 3-SNP combinations
(Table 2), which is again in favor of a true association.
These associations were not observed in a set of much smaller
families. Although statistical type I errors in Set I cannot be totally
discarded here, the discrepancy between the 2 family sets could be
accounted for by a lack of informativity of Set II families. Another
possible explanation could be that the selection of highly
predisposed family enriched Set I for individuals carrying risk
alleles at a smaller number of loci with stronger effects, whereas
psoriasis susceptibility in Set II may be due to a higher number of
Table 3. Comparison of Set I and Set II.
..................................................................................................................................................
A. Description of pedigrees used in the association study
Family set Number
families
Number of
nuclear families
Number of
subjects
Average number of
subjects per family
Number of genotyped
subjects (Affected)
Average number of genotyped
subjects per family (Affected)
Set I 45 295 1161 25.80 926 (346) 20.58 (7.69)
Set II 81 173 668 8.25 539 (235) 7.32 (2.90)
B. Distribution of pedigrees according to the number of nuclear families per pedigree
Number of nuclear families per pedigree 1 2345678 9 1 0 .10 Total
S e t I 1 5562841 2 4 7 4 5
Set II 43 8 16 10 1 2 0 0 1 0 0 81
C. Distribution of nuclear families according to the sibship size
Number of sibships per nuclear families 1 2345678 9 1 0 1 4T o t a l
Set I 75 91 58 31 10 8 11 5 3 2 1 295
S e t I I 4 0 6 64 71 15 4 0 00 00 1 7 3
doi:10.1371/journal.pone.0000906.t003
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Table 4. Univariate SNP analysis in Set II and in combined sets.
..................................................................................................................................................
SNP number SNP ID Gene Set II Set I + Set II
Number of informatives families P
a Number of informatives families P
a
5 rs512625 intergenic 32 0.19 65 0.42
7 rs677044 ADAM33 34 0.98 62 0.10
9 rs628977 ADAM33 35 0.80 69 0.22
10 rs2280089 ADAM33 26 0.62 54 0.96
11 rs2280090 ADAM33 24 0.79 52 0.79
14 rs597980 ADAM33 28 0.50 63 0.17
15 rs44707 ADAM33 35 0.60 71 0.11
16 rs598418 ADAM33 35 0.63 71 0.36
21 rs2787095 ADAM33 36 0.64 70 0.46
23 rs2853213 ADAM33 35 0.84 69 0.34
24 rs2853215 intergenic 30 0.73 61 0.74
25 rs535964 intergenic 32 0.82 67 0.99
26 rs1046919 intergenic 26 0.92 59 0.14
27 rs656635 intergenic 39 0.77 71 0.63
42 rs6076542 SIGLEC1 5-
b 15 0.53
Only SNPs showing some association with psoriasis in Set I, in the univariate or in the 3-SNP haplotype analyses, were tested in Set II.
aFBAT association test P-value under assumption of linkage.
bAssociation test could not be performed due to insufficient number of informative families.
doi:10.1371/journal.pone.0000906.t004
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e906loci with weaker effects. Thus, the contribution of specific
ADAM33 alleles to the familial clustering and individual risk
prediction of psoriasis is likely to be relatively small, and these
issues of case selection should be addressed in future replication
studies.
Nevertheless, our findings can be the source of valuable
physiological insights, since several ADAM33 SNPs have been found
to be associated with asthma and with bronchial hyper-responsive-
ness in Caucasians, in African Americans and in Hispanics [20–22].
An association of ADAM33 with allergic rhinitis has also been
reported in the Japanese population [29]. This first report of an
association between ADAM33 and psoriasis confirms that common
biological pathways may be involved in the etiology of psoriasis and
other clinically distinct immune-mediated diseases.
Although clinical data on inflammatory and autoimmune
diseases other than psoriasis were limited in our family sample,
we examined personal or family history of atopy (AD, asthma and
allergic rhinitis) and of seborrheic dermatitis (SD) retrospectively
from the data available from the questionnaire answered by family
members (Set I). SD was reported in 34 families (75.6%, 128
subjects), AD in 25 families (55.6%, 63 subjects), asthma in 22
families (47.8%, 34 subjects), and allergic rhinitis in 5 families
(10.9%, 5 subjects). These data indicate a higher incidence of
chronic inflammatory diseases in the psoriasis families than in the
general population, except for allergic rhinitis (Incidences of SD,
AD, asthma and allergic rhinitis in France are respectively: 1–3%,
2–5%, 5–7% and 15%) and support the existence of common
genes interacting with other genetic or environmental factors to
result in distinct immunologic abnormalities. As in the general
population, these diseases rarely occurred in the same patient in
our family sample, indicating that susceptibility alleles for these
disorders are likely to be different. Indeed, ADAM33 SNPs that
have been associated with asthma are not the SNPs defining
protective and risk haplotypes for psoriasis [20]. The recently
reported colocalization of the susceptibility loci for psoriasis
(PSORS4) and atopic dermatitis (ATOD2) on Chromosome 1q21
also supports this hypothesis [30]. Although immunologic pro-
cesses in psoriasis and AD are quite different and the two diseases
rarely occur together in the same patient, the possibility of
a specific misregulation of the LOR gene at 1q21, which is down-
regulated in psoriasis, and up-regulated in AD has been suggested
[30]. In the light of our data, the involvement of ADAM33 should
be further investigated in AD as well.
Once an allelic association with the disease has been demon-
strated, the identification of causal variants is less straightforward.
The ADAM33 gene consists of 22 exons that have been re-
sequenced in different populations for SNP identification [20,31].
Of the numerous SNPs described in the public SNP databases,
only 4 validated SNPs occur in the coding region of the gene and,
of these, 3 are non-synonymous. We have excluded an association
between two of them, T764M (rs2280091) and S774P (rs2280090),
and psoriasis (Table 1). The third SNP, A178T (rs3918392), was
also genotyped in our family set, but association tests could not be
performed due to its low frequency (3%) in our population. In
asthma studies, it has been proposed that 39UTR polymorphisms
may be significant [32], although functional investigations of some
of them have so far been unsuccessful [33]. Interestingly, SNP 7
(rs677044) in the 39UTR of ADAM33 showed some association
when analyzed on its own and was present on all 4 most significant
protective haplotypes (Table 2). However, this SNP was also present
on other haplotypes not associated with the disease. Therefore,
a functional role of this SNP in psoriasis susceptibility should be
discarded. Finally, ADAM33 gene undergoes complex alternative
splicing with several variant transcripts and their relative functional
significance to each other is not clear [33,34]. It has been suggested
that some of the ADAM33 polymorphisms may affect alternative
splicing, splicing efficiency or mRNA turnover [20] but such
functional effects for SNP5 (rs512625) in the 39 region of ADAM33
and for SNP14 (rs597980) and SNP15 (rs44707) in intron 19 of the
gene were not investigated in this study.
It has already been noticed that the individual effect of a variant
can be too weak to be detected individually and that interactions of
multiple SNPs within the same gene can affect a phenotype [35].
In complex situations of gene involvement, Jannot et al. showed
that testing combinations of SNPs could provide better power than
testing each single SNP for association [36]. In type 2 diabetes,
CAPN10 and NOD2 are two examples where haplotypes made up
of non-coding variants have been associated with disease
phenotypes in complex fashion while no association was seen in
the univariate SNP analyses [37]. The same situation is observed
in the case of asthma and psoriasis, where the association with
ADAM33 is stronger when combinations of SNPs are examined.
A recent study confirmed that the ADAM33 locus shows
extended linkage disequilibrium upstream of ADAM33 to GFRA4,
as well as downstream including SIGLEC1 (also named sialoadhe-
sin SN) [38]. The region can be divided into 5 haplotype blocks,
ADAM33 being situated between block 4 and 5, with an increased
recombinatory rates around exons S to V of ADAM33. Half of the
SNPs included in the associated combinations here lie in exon S or
upstream (SNPs 5, 7, 9, 10, 11, 15, 16) and the second half lie
downstream exon F (SNP 21, 23, 24, 25, 26, 27). Resolution of LD
maps and block definition at ADAM33 locus is still noisy and it is
likely that yet unidentified variant(s) within the ADAM33 gene or
within distant regulatory elements may be responsible for asthma
or psoriasis. Deep resequencing of the full region would be
required to identify such functional relevant variation.
Psoriasis is a chronic disorder in which T-cell-mediated
inflammation causes thickening of the skin. Conversely, it has
been also hypothesized that in psoriatic patients, the lack of control
of the outer skin cells may lead to the greatly increased production
of cells that characterizes psoriasis. This, in turn, may lead to an
abnormality of the blood vessels and the inflammation character-
istic of psoriasis. Another possibility is that epidermal skin cells fail
to mature into the flat, thickened, ‘‘cornified’’ layer they are
supposed to. As a result, the epidermis tries to produce more cells
than usual leading to the thickened epidermis, which then leads to
inflammation. ADAM proteins have a complex organization that
includes a signal sequence and the following domains: pro,
metalloprotease (including a zinc-binding sequence), disintegrin,
cysteine-rich, epidermal growth factor, transmembrane, and
cytoplasmic tail domains. The proteins have diverse functions
which include adhesion, cell fusion, intracellular signaling and the
shedding of the extracellular portion of proteins such as cytokines
and growth factors, leading to the soluble forms of these proteins.
Expression data suggest that ADAM33 is expressed in most
human tissues, including skin [39]. It is biologically plausible that
ADAM33 is relevant to the development of psoriasis because it
may be involved in the inflammatory response, or in cell-cell and
cell-matrix interactions that are essential for the development and
maintenance of a tissue; likewise, extracellular matrix proteolysis is
an important contributor to skin remodeling, which when altered
might ultimately lead to significant desquamation or, perhaps,
absence of cell maturation.
To conclude with, this is the first report of an association
between ADAM33 and psoriasis. Confirmation of our findings in
different populations would represent an important development
in understanding susceptibility to psoriasis, allergy, and closely
related phenotypes. The importance of this observation should be
The ADAM33 Gene and Psoriasis
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psoriasis.
MATERIALS AND METHODS
Families
The French psoriasis study was approved by the Ethics Committee
of Le Kremlin-Bice ˆtre Hospital in 1995 (CCPPRB) [40]. Briefly,
families were identified through a media campaign between 1996
and 2001 at Ge ´ne ´thon, using posters in the Paris Me ´tro and
information in news magazines, radio and television. Clinical
diagnoses were checked by systematic telephone calls to every
family member, affected or non-affected, for each family, at least
twice during four years by dermatologists using a standard
questionnaire. The attending physician of each patient was also
contacted, usually by mail, which led to confirmation of the
diagnosis in over 75% of cases. Thus, 126 families were enrolled in
the genetic study and provided blood samples. These families were
divided in two non-homogeneous family sets (Set I and Set II): Set
I corresponded to the 45 highly predisposed multigenerational
families used for the initial genome-wide scan, and included on
average 8 affected members per family [11], whereas Set II
corresponded to the 81 remaining smaller families (3 affected
members per family on average, Table 3). One inbred large family
was reported in Set I, with parents who were first cousins (inbred
coefficient for children = 1/16). DNA was extracted from whole
blood using standard procedures after written informed consent of
subjects. The study was conducted in accordance with the
Declaration of Helsinki Principles.
SNP selection
SNPs were initially identified through the HapMap database. A
list of 402 validated SNPs located between the microsatellite
markers D20S864 and D20S112 was generated. In order to
perform a first scanning of the region with a limited number of
SNPs, biallelic markers were filtered according to the following
criteria: selected markers had a minor allele frequency
(MAF)$20% in Caucasian populations, were located within
known genes or nearby (+10 kb upstream and downstream of
known genes), and SNPs with ambiguous flanking sequences were
excluded for genotyping. The population frequencies for the SNPs
were taken from the CEU HapMap population (CEPH collection of
Utah residents of northern and western European ancestry). Thus,
85 SNPs whose position was representative of the overall marker
distribution were eligible for genotyping for Stage I. These SNPs
were located in or near 65 different genes and were not in linkage
disequilibrium with each other (1 SNP/137 kb on average).
To select additional SNPs in the 3 candidate regions on 20p13
(Stage II), different strategies were applied depending on the
availability of SNP data for each candidate gene. When coverage
of a gene with HapMap SNPs was sufficient, we used the Tagger
program to select SNPs that efficiently tagged all common
variations of the candidate genes [41]. This was the case for
SIGLEC1 and AK125945: 17 HapMap tagging SNPs across
SIGLEC1 (Table 1) and five HapMap tagging SNPs across
AK125945 (Supplementary Table S2) were genotyped in family
set I. For these two genes, two additional common SNPs that were
absent in HapMap database (rs1018493, located in exon 6 of
SIGLEC1 and rs1060236, located in the untranslated region of
AK125945) were also genotyped.
When coverage with HapMap SNPs was insufficient, the
density of markers across a candidate was increased using
validated SNPs from dbSNP database or from the literature. This
was the case for ADAM33. This gene had been resequenced in
different populations [20,31], and a number of reported SNPs
were not present in the HapMap database. Therefore, in addition
to 8 HapMap SNPs, 15 other SNPs were selected. Those included
all 3 validated nonsynonymous SNPs (with frequency$5% in
Caucasians) and SNPs that had been previously shown to be
associated with asthma either in univariate or in haplotype analyses.
These SNPs included F_-1 (rs3918392), F_+1 (rs511898), Q_-1
(rs612709), S_1 (rs3918396), ST_+4 (rs44707), ST_+7 (rs574174),
V_-2 (rs628977), V_-1 (rs543749) and V_4 (rs2787094) [20]
(Table 1). Two additional SNPs previously found to be associated
with asthma, V_2 (rs3918400) and V_5 (rs3746631), did not assay
successfully; however, given the moderate to strong levels of LD of
SNPs previously documented, we expected the studied SNPs across
the region to capture most of the haplotypic variation.
Very few SNPs had been identified in GFRA4, despite the fact
that the whole coding sequence of the gene had been resequenced
([42] and personal communication). Therefore, only 4 SNPs were
selected for genotyping in our family set.
Finally for genes within Region 1 (DEFB125, DEFB126,
DEFB127, DEFB128, DEFB129 and DEFB32), incomplete SNP
data were available in the public SNP databases when this study
was initiated. Therefore, we resequenced the entire coding
sequence and the exon/intron junctions of the 6 DEFB genes in
58 unrelated Caucasian controls. Tagging SNPs were identified
using the tagsnps program [43].
SNP genotyping
Genotyping was carried out using TaqmanH according to
manufacturer’s instructions. Primers and probes were supplied
directly by Applied Biosystems as Assays-by-Design
TM. All assays
were carried out in 384-well plates. Each plate included negative
controls (with no DNA) and positive controls were duplicated on
a separate quality control plate. Plates were read on the ABI
PRISM 7900 using the Sequence Detection Software (Applied
Biosystems, Foster City, California, United States). Failed
genotypes were not repeated.
Genotypes were checked for Mendelian inheritance errors using
FBAT [23] and PEDSTATS was used to discard SNPs which
deviate from Hardy-Weinberg Equilibrium in unrelated subjects
[44].
Statistical analyses
Family based association analysis was carried out using the FBAT
program to examine the transmission rates of marker alleles under
the assumption of linkage. The FBAT test is a multiallelic test
based on the classic transmission/disequilibrium test (TDT)
developed by Spielman et al. [45]. It considers parents heterozy-
gous for a certain allele at the marker locus associated with the
disease and evaluates the frequency with which that allele is
transmitted to affected offspring. In each trio, the untransmitted
alleles of the parents serve as controls. The FBAT method permits
analysis of family structures larger than trios. It has been shown
that, when data on parents are missing, one case and two sibs
bring similar power levels to trios and adding sibs when parents
are available increases power [23]. The FBAT software decom-
poses pedigrees into individual nuclear families and treats them as
independent in most of the calculations. The pedigree’s contribu-
tion to the FBAT test statistics is then obtained by summing over
all nuclear families within the pedigree. However, in the case
where linkage is present and the null hypothesis states ‘‘linkage,
but no association’’, the genotypes of the different nuclear families
derived from one pedigree are correlated. Even with a single
nuclear family, the transmissions to multiple sibs are correlated
The ADAM33 Gene and Psoriasis
PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e906when linkage is present. Therefore, when testing for association in
an area of known linkage with multiple sibs in a family or when
multiple families in pedigree occur, an empirical variance for the
test statistics should be used. We used the –e option of FBAT to
compute the ‘‘corrected’’ test statistic, and gave the P-value ‘‘P’’
corresponding to this corrected test statistic. Furthermore,
haplotype analysis was performed using the HBAT function of
FBAT, under the assumption of linkage. This is a method for
estimating genetic association from probabilities of haplotype
transmission to affected offspring. To circumvent the problem of
multiple testing due to the large number of statistical tests
performed simultaneously in the association study, the false
discovering rate was controlled and permutation P-values were
computed with FBAT program (1,000,000 permutation tests were
performed).
Electronic databases and programs
HapMap data are available at http://www.hapmap.org (public
data released nu 6 at 2005-03-01). The dbSNP database is
available at http://www.ncbi.nlm.nih.gov/SNP/. The University
of California Santa Cruz assembly of the genome is available at
http://genome.ucsc.edu/.
The FBAT program version 1.5.5 is available at http://www.
biostat.harvard.edu/,fbat/. PEDSTATS is available at http://
www.sph.umich.edu/csg/abecasis/PedStats/. Tagsnps is available
at http://www-rcf.usc.edu/,stram/tagSNPs.html. Tagger on
Haploview, version 3.2 is available at http://www.broad.mit.
edu/mpg/haploview/using.php.
SUPPORTING INFORMATION
Table S1 Results of the association tests for SNPs selected in
Stage I.
Found at: doi:10.1371/journal.pone.0000906.g001 (0.16 MB
DOC)
Table S2 Results for DEFB genes and for AK125948 gene.
Found at: doi:10.1371/journal.pone.0000906.g001 (0.10 MB
DOC)
Table S3 Pairwise LD (D’) for the 17 SNPs genotyped in the
whole family set.
Found at: doi:10.1371/journal.pone.0000906.g001 (0.02 MB
XLS)
Table S4 Results for HLA-Cw6 tagging SNPs (PSORS1 locus).
Found at: doi:10.1371/journal.pone.0000906.g001 (0.09 MB
DOC)
Table S5 Results for most significant under- and over-trans-
mitted ADAM33 3-SNP haplotypes when stratifying according to
HLA-Cw6 status in patients (for Set I).
Found at: doi:10.1371/journal.pone.0000906.g001 (0.07 MB
DOC)
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